866-997-4948(US-Canada Toll Free)

Muparfostat Analysis and Market Forecasts from 2017 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 28 Pages


GlobalDatas pharmaceuticals report, Muparfostat Analysis and Market Forecasts from 2017 to 2020 provides Muparfostat sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2017-2020). The report also includes information on Liver Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Muparfostat including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Muparfostat including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2017-2020 for Muparfostat in the seven major markets
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of content

1 Table of contents
1 Table of contents 
1.1 List of Tables 
1.2 List of Figures 

2 Introduction 
2.1 Liver Cancer Market 
2.2 Epidemiology 
2.3 Etiology 
2.3.1 Hepatitis B Infection 
2.3.2 Hepatitis C Infection 
2.3.3 Alcohol 
2.3.4 Aflatoxin B1 
2.3.5 Hemochromatosis 
2.3.6 Diabetes and Obesity 
2.3.7 Cirrhosis 
2.4 GlobalData Report Guidance 

3 Liver Cancer : Market Characterization 
3.1 Liver Cancer Market 
3.2 Liver Cancer Market Forecasts and CAGR 
3.3 Drivers for the Liver Cancer Market 
3.3.1 High Incidence 
3.3.2 High Mortality 
3.3.3 Large Unmet Need 

4 Tumor–Node–Metastases (TNM) Classification of Liver Cancer 

5 Muparfostat 
5.1 Introduction 
5.2 Mechanism of Action 
5.3 Clinical Studies 
5.4 Approval of Muparfostat 
5.5 Factors Affecting Sales of Muparfostat 
5.5.1 Only Drug to be Used in Post Liver Resection Adjuvant Settings 
5.5.2 Large Increase in Survival Time 
5.6 Drug Risk Benefit Score 
5.6.1 Efficacy 
5.6.2 Safety 
5.6.3 Compliance 
5.6.4 Dosing Convenience 
5.7 Intensity of Competition 
5.8 Sales Forecast 
5.8.1 Target Patient Pool of Muparfostat 
5.8.2 Dosing 
5.8.3 Market Penetration 
5.8.4 Annual Cost of Therapy 
5.8.5 Sales Projections of Muparfostat 

6 Liver Cancer Market: Appendix 
6.1 Market Definitions 
6.2 List of Abberiviations 
6.3 Research Methodology 
6.3.1 Coverage 
6.3.2 Secondary Research 
6.3.3 Forecasting 
6.3.4 Number of Patients Approved to take the Drug 
6.3.5 Net Penetration of Drug 
6.3.6 Net Annual Dosing 
6.3.7 Annual Cost of Therapy 
6.3.8 Primary Research 
6.3.9 Expert Panels 
6.4 Drug Sales Estimates Model 
6.5 Contact Us 
6.6 Disclaimer 
6.7 Sources 

List of Table


Table 1: Liver Cancer, Incidences and Mortality, 20082030 4
Table 2: Drug Risk Benefit Score (DRB)-Muparfostat 12
Table 3: Annual Cost of Therapy 14
Table 4: Muparfostat, Liver Cancer, Global, Estimated Sales ($m), 20172020 15
Table 5: Muparfostat, Liver Cancer, The US, Estimated Sales ($m), 20172020 16
Table 6: Muparfostat, Liver Cancer, The UK, Estimated Sales ($m), 20172020 17
Table 7: Muparfostat, Liver Cancer, France, Estimated Sales ($m), 20172020 18
Table 8: Muparfostat, Liver Cancer, Germany, Estimated Sales ($m), 20172020 19
Table 9: Muparfostat, Liver Cancer, Italy, Estimated Sales ($m), 20172020 20
Table 10: Muparfostat, Liver Cancer, Spain, Estimated Sales ($m), 20172020 21
Table 11: Muparfostat, Liver Cancer, Japan, Estimated Sales ($m), 20172020 22

List of Chart


Figure 1: Fatality = [(% Distribution of Incidence) (% Distribution of Mortality)] of Most Common Cancers 5
Figure 2: Liver Cancer, Global, Market Size Forecast ($m), 20102020 7
Figure 3: Liver Cancer, Worldwide, Incidence (in millions), 20082030 8
Figure 4: Oncology, Worldwide, Incidence (in millions), 20082030 8
Figure 5: Liver Cancer, Worldwide, Mortality (in millions), 20082030 9
Figure 6: Classification of Liver Cancer 10
Figure 7: Drug Model Diagram of Muparfostat 13
Figure 8: Muparfostat, Liver Cancer, Global, Estimated Sales ($m), 20172020 15
Figure 9: Muparfostat, Liver Cancer, The US, Estimated Sales ($m), 20172020 16
Figure 10: Muparfostat, Liver Cancer, The UK, Estimated Sales ($m) , 2017 2020 17
Figure 11: Muparfostat, Liver Cancer, France, Estimated Sales ($m), 20172020 18
Figure 12: Muparfostat, Liver Cancer, Germany, Estimated Sales ($m) , 20172020 19
Figure 13: Muparfostat, Liver Cancer, Italy, Estimated Sales ($m), 20172020 20
Figure 14: Muparfostat, Liver Cancer, Spain, Estimated Sales ($m),20172020 21
Figure 15: Muparfostat, Liver Cancer, Japan, Estimated Sales ($m), 20172020 22
Figure 16: Muparfostat, Liver Cancer, Global, Sales Distribution (%), 2020 23
Figure 17: Drug Model Diagram 26
Figure 18: Patients Approved for the Drug 26

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *